These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 23660171)

  • 21. Nonmyeloablative hematopoietic cell transplantation. Replacing high-dose cytotoxic therapy by the graft-versus-tumor effect.
    Feinstein L; Sandmaier B; Maloney D; McSweeney PA; Maris M; Flowers C; Radich J; Little MT; Nash RA; Chauncey T; Woolfrey A; Georges G; Kiem HP; Zaucha JM; Blume KG; Shizuru J; Niederwieser D; Storb R
    Ann N Y Acad Sci; 2001 Jun; 938():328-37; discussion 337-9. PubMed ID: 11458521
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Use of mycophenolate mofetil and a calcineurin inhibitor in allogeneic hematopoietic stem-cell transplantation from HLA-matched siblings or unrelated volunteer donors: Japanese multicenter phase II trials.
    Nakane T; Nakamae H; Yamaguchi T; Kurosawa S; Okamura A; Hidaka M; Fuji S; Kohno A; Saito T; Aoyama Y; Hatanaka K; Katayama Y; Yakushijin K; Matsui T; Yamamori M; Takami A; Hino M; Fukuda T
    Int J Hematol; 2017 Apr; 105(4):485-496. PubMed ID: 27943166
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term Outcomes with Nonmyeloablative HLA-Identical Related Hematopoietic Cell Transplantation Using Tacrolimus and Mycophenolate Mofetil for Graft-versus-Host Disease Prophylaxis.
    Ueda Oshima M; Storer BE; Qiu H; Chauncey T; Asch J; Boyer MW; Giaccone L; Flowers M; Mielcarek M; Storb R; Maloney DG; Sandmaier BM
    Transplant Cell Ther; 2021 Feb; 27(2):163.e1-163.e7. PubMed ID: 33830025
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tacrolimus and mycophenolate mofetil after nonmyeloablative matched-sibling donor allogeneic stem-cell transplantations conditioned with fludarabine and low-dose total body irradiation.
    Nieto Y; Patton N; Hawkins T; Spearing R; Bearman SI; Jones RB; Shpall EJ; Rabinovitch R; Zeng C; Barón A; McSweeney PA
    Biol Blood Marrow Transplant; 2006 Feb; 12(2):217-25. PubMed ID: 16443519
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment for acute myelogenous leukemia by low-dose, total-body, irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors.
    Hegenbart U; Niederwieser D; Sandmaier BM; Maris MB; Shizuru JA; Greinix H; Cordonnier C; Rio B; Gratwohl A; Lange T; Al-Ali H; Storer B; Maloney D; McSweeney P; Chauncey T; Agura E; Bruno B; Maziarz RT; Petersen F; Storb R
    J Clin Oncol; 2006 Jan; 24(3):444-53. PubMed ID: 16344316
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intensified Mycophenolate Mofetil Dosing and Higher Mycophenolic Acid Trough Levels Reduce Severe Acute Graft-versus-Host Disease after Double-Unit Cord Blood Transplantation.
    Harnicar S; Ponce DM; Hilden P; Zheng J; Devlin SM; Lubin M; Pozotrigo M; Mathew S; Adel N; Kernan NA; O'Reilly R; Prockop S; Scaradavou A; Hanash A; Jenq R; van den Brink M; Giralt S; Perales MA; Young JW; Barker JN
    Biol Blood Marrow Transplant; 2015 May; 21(5):920-5. PubMed ID: 25687796
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sirolimus and Mycophenolate Mofetil as Calcineurin Inhibitor-Free Graft-versus-Host Disease Prophylaxis for Reduced-Intensity Conditioning Umbilical Cord Blood Transplantation.
    Bejanyan N; Rogosheske J; DeFor TE; Lazaryan A; Arora M; Holtan SG; Jacobson PA; MacMillan ML; Verneris MR; Blazar BR; Weisdorf DJ; Wagner JE; Brunstein CG
    Biol Blood Marrow Transplant; 2016 Nov; 22(11):2025-2030. PubMed ID: 27519278
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetics of oral mycophenolate mofetil in combination with CsA in dogs after nonmyeloablative allogeneic hematopoietic stem cell transplantation.
    Lange S; Mueller SC; Altmann S; Dahlhaus M; Drewelow B; Freund M; Junghanss C
    Bone Marrow Transplant; 2008 Apr; 41(7):667-74. PubMed ID: 18084333
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetics-based optimal dose prediction of donor source-dependent response to mycophenolate mofetil in unrelated hematopoietic cell transplantation.
    Wakahashi K; Yamamori M; Minagawa K; Ishii S; Nishikawa S; Shimoyama M; Kawano H; Kawano Y; Kawamori Y; Sada A; Matsui T; Katayama Y
    Int J Hematol; 2011 Aug; 94(2):193-202. PubMed ID: 21751082
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.
    Takenaka K; Nishida T; Asano-Mori Y; Oshima K; Ohashi K; Mori T; Kanamori H; Miyamura K; Kato C; Kobayashi N; Uchida N; Nakamae H; Ichinohe T; Morishima Y; Suzuki R; Yamaguchi T; Fukuda T
    Biol Blood Marrow Transplant; 2015 Nov; 21(11):2008-16. PubMed ID: 26211985
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Allogeneic hematopoietic cell transplantation for metastatic renal cell carcinoma after nonmyeloablative conditioning: toxicity, clinical response, and immunological response to minor histocompatibility antigens.
    Tykodi SS; Warren EH; Thompson JA; Riddell SR; Childs RW; Otterud BE; Leppert MF; Storb R; Sandmaier BM
    Clin Cancer Res; 2004 Dec; 10(23):7799-811. PubMed ID: 15585611
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cyclosporine and mycophenolate mofetil prophylaxis with fludarabine and melphalan conditioning for unrelated donor transplantation: a prospective study of 22 patients with hematologic malignancies.
    Rodriguez R; Parker P; Nademanee A; Smith D; O'Donnell MR; Stein A; Snyder DS; Fung HC; Krishnan AY; Popplewell L; Cohen S; Somlo G; Angelopoulou M; Al-Kadhimi Z; Falk PM; Spielberger R; Kogut N; Sahebi F; Senitzer D; Slovak M; Schriber J; Forman SJ
    Bone Marrow Transplant; 2004 Jun; 33(11):1123-9. PubMed ID: 15064696
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetics of intravenous mycophenolate mofetil after allogeneic blood stem cell transplantation.
    Jenke A; Renner U; Richte M; Freiberg-Richter J; Platzbecker U; Helwig A; Thiede HM; Schäfer-Eckart K; Ehninger G; Bornhäuser M
    Clin Transplant; 2001 Jun; 15(3):176-84. PubMed ID: 11389708
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetic modelling and development of Bayesian estimators for therapeutic drug monitoring of mycophenolate mofetil in reduced-intensity haematopoietic stem cell transplantation.
    Saint-Marcoux F; Royer B; Debord J; Larosa F; Legrand F; Deconinck E; Kantelip JP; Marquet P
    Clin Pharmacokinet; 2009; 48(10):667-75. PubMed ID: 19743888
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Allografting after nonmyeloablative conditioning as a treatment after a failed conventional hematopoietic cell transplant.
    Feinstein LC; Sandmaier BM; Maloney DG; Maris MB; Gooley TA; Chauncey TR; Hegenbart U; McSweeney PA; Stuart MJ; Forman SJ; Agura EA; Pulsipher MA; Blume KG; Niederwieser DW; Storb RF
    Biol Blood Marrow Transplant; 2003 Apr; 9(4):266-72. PubMed ID: 12720219
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparing morbidity and mortality of HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning: influence of pretransplantation comorbidities.
    Sorror ML; Maris MB; Storer B; Sandmaier BM; Diaconescu R; Flowers C; Maloney DG; Storb R
    Blood; 2004 Aug; 104(4):961-8. PubMed ID: 15113759
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intensive graft-versus-host disease prophylaxis is required after unrelated-donor nonmyeloablative stem cell transplantation.
    Loren AW; Luger SM; Stadtmauer EA; Tsai DE; Schuster S; Nasta SD; Goldstein SC; Perl A; Orloff G; Oliver JC; Green J; Emerson SG; Porter DL
    Bone Marrow Transplant; 2005 May; 35(9):921-6. PubMed ID: 15765118
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects.
    McSweeney PA; Niederwieser D; Shizuru JA; Sandmaier BM; Molina AJ; Maloney DG; Chauncey TR; Gooley TA; Hegenbart U; Nash RA; Radich J; Wagner JL; Minor S; Appelbaum FR; Bensinger WI; Bryant E; Flowers ME; Georges GE; Grumet FC; Kiem HP; Torok-Storb B; Yu C; Blume KG; Storb RF
    Blood; 2001 Jun; 97(11):3390-400. PubMed ID: 11369628
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A randomized phase II trial of tacrolimus, mycophenolate mofetil and sirolimus after non-myeloablative unrelated donor transplantation.
    Kornblit B; Maloney DG; Storer BE; Maris MB; Vindeløv L; Hari P; Langston AA; Pulsipher MA; Bethge WA; Chauncey TR; Lange T; Petersen FB; Hübel K; Woolfrey AE; Flowers ME; Storb R; Sandmaier BM
    Haematologica; 2014 Oct; 99(10):1624-31. PubMed ID: 25085357
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.